Valuation: Axogen, Inc.

Market Cap 2.23B 1.99B 1.85B 1.67B 3.13B 212B 3.18B 22.21B 8.78B 111B 8.37B 8.19B 351B P/E 2026 *
-96.3x
P/E 2027 * 346x
Enterprise Value 2.23B 1.99B 1.85B 1.67B 3.13B 212B 3.18B 22.21B 8.78B 111B 8.37B 8.19B 351B EV / Sales 2026 *
7.81x
EV / Sales 2027 * 6.07x
Free-Float
97.6%
Yield 2026 *
-
Yield 2027 * -
1 day-0.11%
1 week+7.89%
Current month-9.30%
1 month-12.38%
3 months-3.72%
6 months-3.13%
Current year+16.16%
1 week 36
Extreme 36
38.71
1 month 34.11
Extreme 34.11
43.94
Current year 27.54
Extreme 27.54
52.91
1 year 17.14
Extreme 17.14
52.91
3 years 3.45
Extreme 3.45
52.91
5 years 3.45
Extreme 3.45
52.91
10 years 3.45
Extreme 3.45
56.85
Manager TitleAgeSince
Chief Executive Officer 66 08/08/2024
Director of Finance/CFO 42 11/05/2025
Chief Tech/Sci/R&D Officer - 03/01/2024
Director TitleAgeSince
Director/Board Member 65 31/08/2016
Director/Board Member 58 14/05/2019
Chairman 70 08/08/2024
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Sell

Director

-3,500 0.0065%
11/08/26 Exercice

Director

40,059 0.0745%
10/08/26 Exercice

Compliance Officer

202,500 0.3767%
Change 5-day change 1-year change 3-year change Capi.($)
-0.11%+7.89%+109.25%+933.15% 2.23B
+1.64%+0.81%+19.63%+55.60% 253B
+1.07%+3.81%+4.47%+20.29% 164B
-0.15%+4.26%-17.36%+74.03% 157B
-0.24%+1.18%-54.92%-8.44% 66.06B
-1.50%+0.44%+8.59%+67.34% 51.52B
+1.03%+3.07%-14.62%-8.28% 52.64B
+1.67%+3.83%+19.00%+44.25% 52.2B
+1.67%+3.57%+18.87%+68.69% 49.61B
+0.51%+5.00%+26.84%+86.53% 44.8B
Average +0.40%+3.39%+11.97%+133.32% 89.27B
Weighted average by Cap. +0.72%+2.66%+2.69%+48.33%

Financials

2026 *2027 *
Net sales 286M 255M 236M 214M 400M 27.17B 407M 2.84B 1.12B 14.21B 1.07B 1.05B 45B 367M 328M 304M 275M 515M 34.95B 523M 3.66B 1.45B 18.28B 1.38B 1.35B 57.88B
Net income -22.51M -20.13M -18.62M -16.86M -31.56M -2.14B -32.08M -224M -88.65M -1.12B -84.49M -82.69M -3.55B 5.56M 4.97M 4.6M 4.17M 7.8M 529M 7.93M 55.38M 21.91M 277M 20.88M 20.43M 876M
Net Debt - -
Projected Income Statement - Annual - Axogen, Inc.
Logo Axogen, Inc.
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, Avive+ Soft Tissue Matrix, and NerveTape. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
Employees
622
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Axogen, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
38.02USD
Average target price
53.09USD
Spread / Average Target
+39.64%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Axogen, Inc.
  1. Stock Market
  2. Stocks
  3. AXGN Stock